AzTrials
AzTrials

Diabetes MellitusNCT07261800

Sex-specific Differences in the Association Between Leg Fat and Diabetes Risk

An observational study of Diabetes Mellitus and Visceral Adipose Tissue, run by Qianfoshan Hospital at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

This study investigates the association between LFP, VAT and T2DM using DXA in 542 adults. We apply penalized regression, generalized additive models (GAM), and causal mediation analysis to explore whether higher LFP reduces diabetes risk and whether this effect is mediated by VAT. Read more about this study

Who is it for?
Ages 18 to 80 years
What is being tested?
Not Applicable - Retrospective study
How many people
542 participants
Where
1 siteChina
Study dates
31 Dec 2024to 10 Aug 2025
Phase
Observational
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 80 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

Study population: Adults who underwent DXA examination and had complete clinical and biochemical data.

Who may be able to join

  • Adults (≥18 years old)
  • Available DXA measurement of fat distribution
  • Complete fasting glucose or diabetes diagnosis record

Who cannot join

  • Missing key variables (fat distribution, diabetes status)
  • Severe systemic disease interfering with data integrity
  • Implausible or inconsistent records

Trial locations and contacts

1 site in 1 country.

China1 site
  • The First Affiliated Hospital of Shandong First Medical University

    Jinan

Other trials in China

About this study

Official title: Sex-specific Differences in the Association Between Leg Fat and Diabetes Risk: The Mediating Role of Visceral Adipose Tissue

This study investigates the association between LFP, VAT and T2DM using DXA in 542 adults. We apply penalized regression, generalized additive models (GAM), and causal mediation analysis to explore whether higher LFP reduces diabetes risk and whether this effect is mediated by VAT. Sex-specific analyses further clarify the biological differences in adipose distribution. The findings aim to improve understanding of fat distribution and metabolic health.

Read the detailed description

T2DM is a major public health concern, and growing evidence suggests that not all body fat confers equal metabolic risk. Beyond total adiposity, the regional distribution of fat strongly influences insulin resistance and diabetes development. VAT is metabolically detrimental, promoting inflammation and lipotoxicity, whereas lower-body subcutaneous fat, particularly in the legs and gluteofemoral region, may exert protective metabolic effects by serving as a "safe storage" depot for excess lipids. However, the causal mechanisms underlying these associations remain incompletely understood, and whether the protective role of LFP differs by sex remains unclear.

This study aims to elucidate the metabolic and causal pathways linking LFP, VAT, and diabetes risk in adults. Using DXA for precise body composition assessment, the study evaluates the associations between LFP, VAT, and T2DM prevalence, with a focus on sex-specific effects. A total of 542 adult participants will be analyzed, including both men and women with and without T2DM. Clinical, biochemical, and anthropometric data will be collected concurrently.

The analytic framework integrates multiple complementary approaches:

  1. Penalized regression models (LASSO, ridge, elastic net) will identify the most predictive adiposity components for T2DM while minimizing collinearity.
  2. GAMs will examine potential nonlinear relationships between LFP, VAT, and diabetes risk, separately for male and female.
  3. Causal mediation analysis will quantify the extent to which VAT mediates the relationship between LFP and diabetes, providing mechanistic insight into adipose redistribution pathways.
  4. Inverse-probability-of-treatment weighting (IPTW) will strengthen causal inference by balancing covariates across LFP strata.
  5. Two-sample Mendelian randomization (MR) will further test the causal effect of genetically predicted LFP on T2DM risk using summary-level genome-wide association data.

We hypothesize that higher LFP will be associated with lower diabetes risk and that this protective effect will be partially mediated by reduced VAT accumulation, particularly in females.

This study integrates imaging-based body composition, causal modeling, and genetic validation to bridge observational and causal evidence. The findings are expected to improve the understanding of sex-specific fat distribution in metabolic health and support the development of personalized prevention strategies targeting regional adiposity rather than total body fat.

Being tested
Not Applicable - Retrospective study
Medical subject headings
Diabetes Mellitus

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Not Applicable - Retrospective studyOther

    Not Applicable - Retrospective study

Study groups in NCT07261800
Study groupRoleWhat they receive
diabetes groupParticipants diagnosed with type 2 diabetes based on clinical guidelines, including elevated fasting plasma glucose (FPG) and/or HbA1c levels. This group will help assess how regional fat distribution (particularly leg-fat percentage) correlates with T2D risk.
Receives: Other: Not Applicable - Retrospective study
non-diabetes groupParticipants without T2DM, with normal glucose metabolism and no history of insulin resistance. This group is used as a reference for comparing the metabolic effects of adipose distribution with the T2DM group.
Receives: Other: Not Applicable - Retrospective study

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Prevalence of diabetes in relation to lower extremity fat

    T2DM will be defined according to standard diagnostic criteria (fasting plasma glucose ≥ 7.0 mmol/L and/or HbA1c ≥ 6.5%, or a physician diagnosis). The primary outcome is the association between LFP and diabetes status, estimated using multivariable logistic regression and causal mediation analysis.

    Measured: Baseline

Secondary outcomes (2)
  1. Mediating Effect of VAT

    Quantification of the indirect effect of VAT in the association between LFP and T2DM risk, estimated via causal mediation analysis.

    Measured: baseline

  2. Sex-specific Differences in the LFP-T2D Association

    Evaluation of whether the association between LFP and diabetes risk differs between males and females using sex-stratified models and interaction testing.

    Measured: Baseline

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted3 Dec 2025
  2. Study start31 Dec 2024
  3. Primary completion12 Feb 2025
  4. Study completion10 Aug 2025

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Observational
Observational model
Cohort
Time perspective
Retrospective
Enrolment
542 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT07261800
Sponsor's protocol ID
S877
Status last verified
Sep 2025
First submitted
9 Sep 2025
Last updated
3 Dec 2025
Results posted
No
FDA-regulated drug
No
FDA-regulated device
No
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

An observational study of Diabetes Mellitus and Visceral Adipose Tissue, run by Qianfoshan Hospital at 1 site in China.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 3 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Prevalence of diabetes in relation to lower extremity fat (time frame: Baseline). It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 3 Dec 2025.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in